Jefferies Group LLC Reaffirms Buy Rating for Puretech Health PLC (PRTC)
Jefferies Group LLC reiterated their buy rating on shares of Puretech Health PLC (LON:PRTC) in a research report sent to investors on Wednesday morning. They currently have a GBX 225 ($2.91) target price on the stock.
Several other brokerages have also commented on PRTC. N+1 Singer restated a buy rating on shares of Puretech Health PLC in a research report on Wednesday. Numis Securities Ltd restated a buy rating and set a GBX 246 ($3.18) target price on shares of Puretech Health PLC in a research report on Wednesday. Liberum Capital restated a buy rating and set a GBX 248 ($3.21) target price on shares of Puretech Health PLC in a research report on Wednesday. Finally, Peel Hunt restated a buy rating and set a GBX 259 ($3.35) target price on shares of Puretech Health PLC in a research report on Tuesday. Five equities research analysts have rated the stock with a buy rating, Puretech Health PLC presently has a consensus rating of Buy and a consensus price target of GBX 246.80 ($3.19).
Puretech Health PLC (LON PRTC) opened at 137.50 on Wednesday. The firm’s market capitalization is GBX 319.98 million. Puretech Health PLC has a 1-year low of GBX 110.00 and a 1-year high of GBX 170.00. The company has a 50 day moving average of GBX 133.48 and a 200 day moving average of GBX 121.39.
Puretech Health PLC Company Profile
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Stock Ratings for Puretech Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health PLC and related stocks with our FREE daily email newsletter.